ESMO Breast 2022 | The use of the Ki-67 in deciding which patients with HR+ breast cancer can safely avoid chemotherapy

Name: The use of the Ki-67 in deciding which patients with HR+ breast cancer can safely avoid chemotherapy
Uploaded: 2022-05-04T00:00:00Z
Duration: 1 min 21 s
Description: Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, talks on the use of the Ki-67 score in patients with HR-positive breast cancer to optimize the decision making on who can benefit from endocrine treatment and avoid chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

Sung-Bae Kim • 4 May 2022

ESMO Breast 2022

Breast Cancer

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, talks on the use of the Ki-67 score in patients with HR-positive breast cancer to optimize the decision making on who can benefit from endocrine treatment and avoid chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.